Difei Yang

Stock Analyst at Mizuho

(2.16)
# 2,889
Out of 5,050 analysts
33
Total ratings
31.03%
Success rate
11.79%
Average return

Stocks Rated by Difei Yang

Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6$2
Current: $2.04
Upside: -1.96%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229$200
Current: $10.92
Upside: +1,731.50%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.38
Upside: +2,653.62%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $11.03
Upside: +6,472.98%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $27.79
Upside: +87.12%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158$160
Current: $17.63
Upside: +807.54%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18$14
Current: $7.43
Upside: +88.43%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315$525
Current: $55.97
Upside: +838.00%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.22
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $11.21
Upside: +149.78%
Initiates: Buy
Price Target: $28
Current: $1.10
Upside: +2,445.45%